


Contact us for any enquiries

Dr Andrew Carnegie

Head of Strategic Development

 [andrew.carnegie@inaphaea.com](mailto:andrew.carnegie@inaphaea.com)

 +44(0)7932 035029

Follow us on social media

 @Inaphaea BioLabs

 @Inapahea



Comparison of PDCs to other oncology models

Model	Phenotype/ Genotype to Original Patient Tissue	Model Development Success Rate	HTS/HCS Ability	Speed of Assay	Cost	Clinical Correlation	Heterogeneity (Stroma, etc.)	Immune Component
Immortal Cell Line	-	++	+++	+++	\$	-	-	-
Patient Derived Cell Model (PDC) *	+++	+++	+++	+++	\$\$	++	+	+/-
Patient Derived Organoid (PDO)	+++	++	++	++	\$\$	++	+	+/-
Cell Line Xenograft (CDX)	-	++	+/-	++	\$\$	-	-	-
Patient Derived Xenograft (PDX)	+++	+	+/-	+	\$\$\$	++	++	+/-

\* Currently evaluating feasibility of P DC-Xenografts (PDC-X) with in vivo service providers




## Custom assay development for advanced drug discovery

**Inaphaea Biolabs** is a translational contract research organisation offering cell-based assays specialising in oncology.

Spun out from ValiRx PLC, the core team within Inaphaea have a strong background of preclinical and clinical drug development, and of understanding both the commercial and scientific needs of the service users from both sides of the table.


Our aim is to improve the translation of early drug discovery projects towards the clinic.

Driven by a desire to generate deeper biological understanding of drug candidates in discovery and preclinical phases of development, Inaphaea provide testing services that generate the necessary data, analysis and insights to aid decision making in translational drug development.



## Patient derived cells (PDC)

- Solid tumour models available across a range of cancer types (2D/3D) with hypoxia assays
- Models include basic demographics
- Model handling sheets available
- Available for use in our services
- RNAseq data available for model selection and training sets
- Provides more relevant cancer cell models for cell assay screening
- Enables development of personalised cancer models
- Available under straightforward, no-nonsense commercial use license agreements:
  - No reach-through milestones or royalties when your product is a success
  - Choice of annual fee or one-off payment
  - Only restrictions around non-competition with Inaphaea BioLabs



## Combined service offerings from our partners under a single contract

### Agility Life Sciences

Formulation work checks your molecule is stable and soluble under our assay conditions.

### Ignota Labs

Ignota Labs utilise AI to explore potential toxicity and lead optimisation.

### Inspiralis

Enzyme Assay experts who explore enzyme kinetics for lead optimisation.

### Physiomics

Use advanced modelling and data handling to understand your assay results.

### DefiniGEN

Profile drug candidates for liver disease and liver toxicity using in vitro, iPSC-derived, hepatocyte assays.

### HistologiX

Cell histology can stain your cells and examine them.

### OncoBone

A virtual CRO service bringing together the breadth of CRO capabilities, advertising us as their in vitro offering.

### Imagen Therapeutics

Developed the biobank of patient derived cells now owned by Inaphaea.

### Scientist.com

We advertise on scientist.com to simplify documentation if you also use this service.